Tests canagliflozin in adults on peritoneal dialysis for kidney failure
Tests canagliflozin, a diabetes pill, in adults receiving peritoneal dialysis for kidney failure.
Plain-language title generated from the registry record
Registry title: Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis
Key facts
- Where
- Montreal, CanadaSee the site
- Phase
- Phase 2
Where in Canada
- Research Institute-McGill University Health CenterMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Trial code
- NCT06913647
- Record updated
- 16 March 2026
- Original description
This is a phase II, proof-of-concept, placebo-controlled, double-blind, cross-over randomized clinical trial, assessing the effect of canagliflozin on peritoneal membrane function in patients on PD.Read full original descriptionShow less
Effect of Canagliflozin on Ultrafiltration and Fibrosis in Peritoneal Dialysis: a a Proof-of-concept Randomized Phase II Crossover Clinical Trial
This is a phase II, proof-of-concept, placebo-controlled, double-blind, cross-over randomized clinical trial, assessing the effect of canagliflozin on peritoneal membrane function in patients on PD.
The primary aim of this trial is to determine the short-term effects of canagliflozin, an SGLT-2 inhibitor, on glucose absorption by the peritoneal membrane and on ultrafiltration, as assessed by a standardized peritoneal equilibrium test. The secondary aims are to determine the effect of canagliflozin on solute clearance and on effluent biomarkers of inflammation, angiogenesis, and fibrosis at 26 weeks. We hypothesize that canagliflozin will prevent glucose absorption by the peritoneal membrane, as compared with placebo, and will attenuate the development of inflammation, angiogenesis, and fibrosis of the peritoneal membrane, as assessed by relevant biomarkers in the dialysate.
Inclusion: Adult patients with kidney failure on PD (both incident and prevalent) who are on a stable prescription of dextrose-based solutions for at least 3 months; Only high or high-average transporters, as classified by PET, will be included.
Exclusion: Kidney transplant scheduled in the next 6 months; Patients receiving digoxin, phenobarbital, phenytoin, rifampin, or ritonavir if these agents cannot be safely discontinued; History of euglycemic ketoacidosis; Known hypersensitivity to canagliflozin; Active peritonitis or tunnel infection; Recurrent severe genital or urine infections; Severe liver cirrhosis (Child-Pugh class C stage); Pregnancy or breastfeeding.